Summary
Background: Many UK hospitals have set-up specialised chest pain clinics to deal promptly and efficiently with cases of possible cardiac chest pain. It is possible that a proportion of patients attending these clinics will have a respiratory cause for their chest pain, or respiratory disease in addition to their cardiac pain. This study aimed to determine the prevalence of airflow obstruction, ischaemic heart disease and dual pathology in such patients. Methods: Spirometry was performed on patients referred to a rapid access chest pain clinic over a 12-month period (target population of 400 patients). The main outcome measure was the prevalence of airflow obstruction (defined using spirometry), ischaemic heart disease and dual pathology. Results: 405 subjects participated in the study. Abnormal spirometry was detected in 21% of patients (n Z 85). Airflow obstruction was the predominant lung function abnormality and was detected in 60 patients. Ischaemic heart disease was diagnosed in 21% of patients (n Z 85). Dual pathology was found in 4% of patients (n Z 17). Conclusions: Previous studies have reported a link between impaired lung function and future cardiovascular morbidity and mortality. This study suggests that airflow obstruction is an important alternative differential diagnosis in patients referred to a rapid access chest pain clinic. The identification of abnormal spirometry may help to better risk-stratify patients for future cardiovascular events and allow interventions to be instituted. ª 2008 Elsevier Ltd. All rights reserved.
Introduction
In order to deal promptly and efficiently with cases of possible cardiac chest pain, specialised rapid access chest pain clinics (RACPCs) have been set-up in many hospitals in the United Kingdom. The evaluation of the patients referred to these clinics has, however, been almost entirely devoted to the exclusion of cardiac cause, and investigation of a non-cardiac cause is rarely undertaken. Both Ischaemic Heart Disease (IHD) and respiratory diseases such as Chronic Obstructive Pulmonary Disease (COPD) share smoking as a common risk factor, 1,2 and respiratory disease is another important cause of chest pain. 3 We hypothesised that a proportion of patients attending such clinics will have a respiratory cause for their chest pain, or will have respiratory disease in addition to their cardiac pain, which may be overlooked or remain untreated. Our study aimed to determine the prevalence of airflow obstruction (AO), IHD and the co-existence of both conditions (dual pathology) in patients attending a rapid access chest pain clinic.
Methods
The study was conducted in accordance with the recommendations found in the Helsinki Declaration of 1975 4 and was approved by Wrightington, Wigan and Leigh Research Ethics Committee.
Subjects were recruited over a 12-month period from the South Manchester University Hospital Trust rapid access chest pain clinic (RACPC) and all subjects provided written, informed consent to participate. As far as we are aware, rapid access chest pain clinics are unique to the UK and are defined as a cardiologist-supervised facility for the assessment of patients with recent onset chest pain. Patients who develop symptoms that their General Practitioners (GPs) think may be caused by ischaemic heart disease are referred to the RACPC and should be assessed within two weeks. This was part of the recommendations made by the National Service Framework for Coronary Heart Disease 5 in order to ensure that people who develop new symptoms can be quickly assessed by a specialist. The referral criteria for the clinic are: recent onset cardiac sounding chest pain within the previous six weeks, no previous history of ischaemic heart disease, not previously assessed in outpatients or as an inpatient for chest pain and unstable angina or myocardial infarction not suspected. Only patients whose appointment allowed for 24 h consideration of the consent were allowed to participate. Subjects unable to complete questionnaires (without assistance), due to English language proficiency or visual impairment were excluded.
Standard clinic protocols were followed for assessment of cardiac cause. Patients had an electrocardiogram (ECG) performed on arrival in the clinic and were then seen and assessed by a specialist nurse and cardiologist. A history and examination were undertaken and an exercise ECG was performed if appropriate. The exercise testing was carried out using the Bruce protocol, 6 which is widely used to perform exercise tests. Where patients were unable to carry out the exercise test, or the test was inconclusive (for example the patient was not able to exercise for a sufficient period of time) additional tests were organised such as echocardiogram, dobutamine stress echocardiography or myocardial perfusion scan. Suitable patients who were thought to have angina were placed on a waiting list for angiography. All patients who wished to participate in the study (regardless of their cardiac diagnosis) were then recruited.
Spirometry testing was then performed according to American Thoracic Society guidelines (1994 update) 7,8 using a Microlab desktop spirometer (Micro Medical Ltd, Rochester, Kent). European Community for Steel and Coal (ECCS) predicted values were used and an ethnic correction factor was applied where appropriate. 7, 8 Forced expiratory volume in 1 s (FEV 1 ), forced vital capacity (FVC) and FEV 1 / FVC ratio were determined. Reversibility testing was not performed as part of this study, hence all values were prebronchodilator. Subjects were classified as having airflow obstruction using ATS/ERS task force guidelines, 9 with AO being defined as an FEV 1 /FVC ratio 0.70. In addition, severity of airflow obstruction was based on FEV 1 percent predicted values: mild AO was defined as FEV 1 80% predicted, moderate AO as FEV 1 50e80% predicted, severe COPD as FEV 1 30e50% predicted and very severe AO as FEV 1 <30% predicted. Subjects were classified as ''at risk'' of COPD if they had normal lung function, but a pack year smoking history of 20 years or more, or symptoms of cough, sputum or dyspnoea. Restrictive spirometry defects were classified as FEV 1 /FVC ratio 0.70 and FVC <80% predicted. The results of the spirometry were explained to the participant and a letter explaining the results, suggesting treatment and/or further investigation was sent to the general practitioner.
Wythenshawe Community Asthma Project questionnaire 10 and Medical Research Council (MRC) dyspnoea score 11 questionnaires were completed. For the purposes of the analysis, the MRC scores were categorised as <3 or 3.
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Diagnosis of IHD was obtained from the medical records after the clinic visit (once results of any further tests carried out such as angiograms or echocardiograms had been reported). Diagnosis of airflow obstruction was determined at the study visit (from spirometry results). The prevalence of these diseases in patients referred to rapid access chest pain clinics was determined.
Statistics
Characteristics of the populations with and without AO and with and without IHD were compared. Categorical variables were compared using Chi squared tests and continuous variables were compared using t-tests. All analyses were carried out using the Statistical Package for the Social Sciences (SPSS) Version 13.0 for Windows (SPSS Inc., Chicago, IL, USA).
Results
Our target population was patients who attended the RACPC between 11th February 2005 and 6th February 2006. Six hundred and seventy patients attended the clinic during this time, of whom 483 were eligible to take part as they had received our letter of invitation. Four hundred and five patients participated in the study. We therefore achieved a response rate of 84% of the eligible population and 60% of the total population. 403 patients performed adequate lung function tests. Characteristics of the patients recruited are presented in Table 1 . The mean age was 56 with a range 21e88 years, with the majority (62.5%, n Z 253) being current or ex-smokers.
Ischaemic heart disease diagnosis was not available for 4 subjects due to their failure to attend for additional tests that were required. Eighty-five patients (21%) were diagnosed as having ischaemic heart disease. Significantly most of the patients with either IHD alone or dual pathology were male (c2 Z 10.13; p < 0.001). The prevalence of ischaemic heart disease in those subjects who were current or exsmokers was 22.5%.
Eighty-five subjects (21%) were found to have abnormal lung function ( Table 2 ). Both restrictive and obstructive patterns were seen. The prevalence of abnormal lung function in those patients who were current or ex-smokers was 27.7%. Sixty subjects were classified from spirometry results as having airflow obstruction. Eighty-eight percent of subjects with AO were current or ex-smokers (and 86% of subjects with AO alone were current or ex-smokers). Twenty-five subjects were identified as having a restrictive defect. However, two of these subjects had an obstructive spirometry pattern (reviewed by a respiratory physician), but were unable to reach FVC and were therefore categorised as restrictive.
Forty-three subjects (10.6% of entire group) had AO alone, and 17 subjects (4.2%) had dual pathology. Of the 60 subjects with AO, 7 (11.7%) had a prior history of asthma and 7 (11.7%) had a previous history of COPD. Thirteen of the fourteen subjects with a previous history of airflow obstruction were on treatment with inhaled corticosteroids and/or bronchodilators. Fifty-four of all the subjects studied had a prior diagnosis of asthma or COPD, of which Fig. 1 .
Descriptive analysis of the data (Table 3) showed that subjects with airflow obstruction were more likely to have experienced symptoms of wheeze, phlegm production and chronic productive cough or phlegm and have an MRC dyspnoea score of 3 or more. In addition to having significantly lower lung function (FEV 1 percent predicted, FVC percent predicted and FEV 1 /FVC ratio), subjects with AO were significantly older and had higher smoking pack year history. The mean age of the subjects with AO was 61 years, and 4 (7%) of these subjects were over 75 years of age. Subjects with IHD were more likely to be male and were significantly older than patients with no IHD (Table 4 ). The mean age of the subjects with IHD was 64 years, and 12 (14%) of subjects with IHD were over 75 years of age. The mean FEV 1 /FVC ratio was lower in those subjects with IHD compared with no IHD diagnosis.
Discussion
The principal aim of this study was to determine the prevalence of airflow obstruction, IHD and dual pathology in patients attending a chest pain cardiology clinic. We found that a significant proportion of these patients had abnormal spirometry, with the majority showing evidence of AO. The same proportion of participants was diagnosed with IHD as were found to have abnormal spirometry.
The prevalence of ischaemic heart disease detected in this study was similar to that of a multi-centre study of patients with chest pain attending RACPCs at six Hospitals in England. 13 In this recent study, angina was diagnosed in 27% of patients.
It is possible that the signs and symptoms of chest pain may differ between patients with airflow obstruction and those with ischaemic heart disease. However, we did not assess this as part of this study as one of the referring criteria was that the patients should have cardiac sounding chest pain.
Both obstructive and restrictive spirometry patterns were seen. Twenty-five subjects were classified as having a restrictive defect. There is evidence that cardiac enlargement and heart failure (HF) can result in a restrictive lung function pattern, thought to be due to intrathoracic space limitation impairing the lungs ability to fill. 14 However, we have no data for cardiomegaly or HF prevalence in our patient population. Obesity is also associated with restrictive spirometry. 15 Nineteen of the twenty-five (76%) subjects with a restrictive pattern had a BMI in the overweight (25e29.9) or obese (30) category.
We used an empirical level of 0.70 for FEV 1 /FVC ratio (pre-bronchodilator) in order to define airflow obstruction. Had we included reversibility testing in our protocol, we may have been better able to differentiate between a diagnosis of asthma or COPD. However, there was insufficient time during the clinic sessions to allow two sets of lung function Prevalence of airflow obstruction in patients attending a rapid access chest pain clinicmeasurements to be performed. Using a threshold of 0.70 for FEV 1 /FVC ratio is widely used to define airways obstruction 16 and has been adopted for simplicity in order to aid uptake of spirometry as a clinical tool. However, there is the potential for miss-classification since the FEV 1 /FVC ratio falls with increasing age. 17e19 This may lead to over-diagnosis in the elderly and the potential for under-diagnosis in younger adults. 20 Of the sixty subjects identified as having AO, four (7%) were seventy-five years of age or above. Although these weaknesses relating to misdiagnosis may have slightly influenced the total identified prevalence of airflow obstruction, it is likely that the findings are close to that which we would have found with more rigorous investigations (such as including reversibility, lung volumes and transfer factor measurements). More complex investigations would have been impractical to carry out in this study due to time constraints.
Another limitation of this study relates to the overall response rate of 60%. We are not able to ascertain the cardiac or respiratory status of the patients who were not eligible to take part or refused, which may confound the results. Very few participants refused to participate (84% of eligible patients agreed to take part). It was a requirement of the ethical approval for the study that patients had at least 24 h (from being provided with the information sheet) to decide whether or not they wished to take part. In the majority of cases the reason that patients were not eligible was that their appointment had been at very short notice, which did not allow sufficient time for them to receive the information letter. Since this occurred when the referral rate slowed down and was related to the availability of short notice appointments (often arranged by telephone on the same day as the GP referral had been made) rather than particular patients being prioritized on clinical need, we feel that this is unlikely to have introduced a significant amount of bias.
Although cigarette smoking is the principle risk factor for COPD, occupational factors are thought to contribute to disease amongst non-smokers or magnify the influence of smoking on individuals who smoke. A large population based survey estimated that the fraction of COPD attributable to work was 19.2% overall and 31.1% among never smokers. 21 Seven (11.7%) of the subjects identified as having AO in this study had never smoked. We did not collect any data on occupational exposures as part of this study and therefore cannot exclude this as a contributing factor in some of the subjects.
Of the eighty-five subjects found to have abnormal spirometry in this study, sixty-eight (80%) had no previous diagnosis of asthma or COPD. This finding is important as identifying lung disease such as COPD allows interventions to slow the rate of disease progression to be initiated, such as 25 and future cardiovascular mortality. 26e35 The participants of this study were relatively young, hence avoidance of risk factors in this group of patients could improve their prognosis, in terms of both lung and cardiovascular disease. The measurement of spirometry in patients attending healthcare clinics such as this would be an ideal opportunity to detect abnormalities in lung function that may otherwise be missed, and would be particularly valuable for those patients with a significant smoking history.
This study suggests that airflow obstruction may be an important alternative differential diagnosis in patients referred to a secondary care chest pain clinic. Furthermore, the identification of abnormal spirometry provides additional prognostic information which may help to better risk-stratify patients for future cardiovascular events and allow interventions to be instituted. However, the patient selection in this study is unusual in comparison to studies of COPD prevalence in other countries due to the nature of this clinic service.
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